United States· US:55513-222_74d31919-0ed2-4e98-abd8-7cc3e011646b
Nplate
A romiplostim product containing romiplostim, registered in United States by Amgen, Inc. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Romiplostim is registered in 14 of 19 countries.
Countries holding a registration under ATC B02BX04 (romiplostim), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Romiplostim · ATC B02BX04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of romiplostim costs, country by country.
Normalised to the WHO defined daily dose (30 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Romiplostim · price per daily dose (30 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$72.77
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- romiplostim
- Manufacturer
- Amgen, Inc
- Country
- United States (US)
- ATC code
- B02BX04
- ATC class
- Romiplostim
- Defined daily dose
- 30 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 2
- ndc1155513222011 VIAL in 1 CARTON (55513-222-01) / 1 mL in 1 VIAL
- ndc1155513222211 VIAL in 1 CARTON (55513-222-21) / 1 mL in 1 VIAL
Regulatory notes
Interactions
2 interactions on record for romiplostim.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Romiplostim · interactions on record
2 records
- 2 severe
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Romiplostim in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNPLATEAmgen Europe B.V., Breda
- BelgiumNplate 125 µgAmgen Europe
- FinlandNplateAmgen Europe B.V.
- IcelandNplateAmgen Europe B.V.*
- PolandNplateAmgen Europe B.V.
- SwedenNplate 125 mikrogram Pulver till injektionsvätska, lösningAmgen Europe B.V.
- SpainNPLATE 250 microgramos POLVO PARA SOLUCION INYECTABLEAmgen Europe B.V.
- IrelandNplate 250 microgramsAmgen Europe B.V.,
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Nplate
- Norway · Nplate
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/63892db0-6d70-4a0d-b6c3-6de3f1370ac8 GET /v1/drugs/63892db0-6d70-4a0d-b6c3-6de3f1370ac8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "GN5XU2DXKV",
"rxcui": "805452",
"inchikey": null,
"display_name": "ROMIPLOSTIM",
"substance_type": "protein",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"spl_meta": {
"c45f9a58-37c1-4f76-8e36-97d38c577037": {
"match": "brand_token",
"title": "NPLATE (ROMIPLOSTIM) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [AMGEN, INC]",
"spl_version": "161",
"published_date": "2026-03-12"
}
},
"productid": "55513-222_74d31919-0ed2-4e98-abd8-7cc3e011646b",
"productndc": "55513-222",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "ROMIPLOSTIM",
"proprietary_name": "Nplate",
"active_ingred_unit": "ug/mL",
"application_number": "BLA125268",
"marketing_category": "BLA",
"nonproprietary_name": "romiplostim",
"start_marketing_date": "20080825",
"active_numerator_strength": "500"
}See everything about romiplostim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.